DEVICE AND METHOD FOR INTRAOCULAR DRUG DELIVERY

• US 20100074942A1
• Filed: 09/11/2009
• Published: 03/25/2010
• Est. Priority Date: 03/14/2007
• Status: Abandoned Application

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Shen, Tueng T., Ratner, Buddy D.
• Application Number:
  US12/558,391
• Publication Number:
  US 20100074942A1
• Time in Patent Office: Days
• US Class Current: 424/429
• CPC Class Codes: A61F 2/16 Intraocular lenses
• CPC Class Codes: A61F 2/1694 Capsular bag spreaders therefor
• CPC Class Codes: A61F 2002/16901 Supporting structure conforms to shape of capsular bag
• CPC Class Codes: A61F 2250/0068 the pharmaceutical product being in a reservoir
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: Y10T 29/53987 Tube, sleeve or ferrule

Abstract

Intraocular devices having a drug delivery construct attached thereto, and methods for using the devices for intraocular drug delivery and the treatment and/or prevention of conditions.

Claims

1. An intraocular device having one or more drug delivery constructs attached thereto, each drug delivery construct comprising a polymeric or hydrogel substrate having a surface with a plurality of alkyl groups covalently coupled thereto, wherein the construct includes a therapeutic drug compound.

2. The device of claim 1, wherein the intraocular device is an intraocular lens or a capsular tension ring.

3. The device of claim 1, wherein the alkyl groups are C₁₀ to C₂₂ unbranched alkyl groups.

4. The device of claim 1, wherein alkyl groups are C₁₂ to C₁₈ unbranched alkyl groups.

5. The device of claim 1, wherein the greater the number of alkyl groups the slower the release of the therapeutic drug compound from the construct.

6. The device of claim 1, wherein the substrate comprises poly(2-hydroxyethyl methacrylate).

7. The device of claim 1, wherein the substrate comprises two or more therapeutic drug compounds.

8. The device of claim 1, wherein the therapeutic drug compound is selected from the group consisting of an antibiotic compound, an anti-inflammatory compound, an ophthalmic beta-blocker, a carbonic anhydrase inhibitor, an alpha-agonist, a miotic compound, and a prostaglandin analog.

9. The device of claim 2, wherein the intraocular lens comprises:

(a) an optic means having an anterior and a posterior surface and a periphery;

(b) at least two resilient haptic means, the haptic means having at least one end thereof secured to the optic means with the haptic means extending outwardly from the periphery of the optic means; and

(c) at least two haptic engaging means formed on the posterior surface of the optic means adjacent the periphery thereof for selectively releasably retaining the haptic means in an inwardly flexed position in proximate relation to the periphery of the optic means, the haptic engaging means being positioned for engagement with the haptic means at a position intermediate the ends thereof.

10. The device of claim 2, wherein the capsular tension ring comprises a loop formed of biocompatible material, the loop being operable to generally prevent shrinkage of the capsular bag following implantation therein.

11. The device of claim 1, wherein the therapeutic drug compound is norfloxacin hydrochloride.

12. A method for intraocular drug delivery, comprising inserting the intraocular device of claim 1 into the eye of a subject in need thereof.

13. The method of claim 12, wherein the intraocular device is an intraocular lens or a capsular tension ring.

14. The method of claim 12, wherein the therapeutic drug compound is selected from the group consisting of an antibiotic compound, an anti-inflammatory compound, an ophthalmic beta-blocker, a carbonic anhydrase inhibitor, an alpha-agonist, a miotic compound, and a prostaglandin analog.

15. A method of treating and/or preventing a disease or condition, comprising introducing the intraocular device of claim 1 into the eye of a subject in need thereof.

16. The method of claim 15, wherein the disease or condition is an infection.

17. The method of claim 15, wherein the intraocular device is an intraocular lens or a capsular tension ring.

18. The method of claim 15, wherein the therapeutic drug compound is selected from the group consisting of an antibiotic compound, an anti-inflammatory compound, an ophthalmic beta-blocker, a carbonic anhydrase inhibitor, an alpha-agonist, a miotic compound, and a prostaglandin analog.

19. A kit for attaching a drug delivery construct to an intraocular device, comprising:

(a) a tube with one or more drug delivery constructs attached thereto, each drug delivery construct comprising a polymeric or hydrogel substrate having a surface with a plurality of alkyl groups covalently coupled thereto, wherein the construct includes a therapeutic drug compound; and

(b) a tool for removing the drug delivery constructs from the tube to an intraocular device.